Logo
Login
$CLNN
$3.97 +$0.13 (3.39%) Close

Company Executives

$CLNN Management Team

Mr. David Matlin

Independent Chairman of the Board

Age 63
Compensation $86.68K USD
Sex Male

Mr. Robert Etherington

President

Chief Executive Officer

Director

Age 58
Compensation $1.368M USD
Sex Male

Mr. Mark Mortenson

Co-Founder

Chief Science Officer

Age 65
Compensation $1.079M USD
Sex Male

Mr. Morgan Brown

Chief Financial Officer

Age 55
Compensation $760.6K USD
Sex Male

Board of Directors

From the proxy statement filed Apr 10, 2026
Directors
9
serving now
Independent
8 of 8
stated in the proxy; 1 not stated
Average tenure
7.7 years
from year joined
CEO also chairs the board
No
David J. Matlin
Director Age On board Independent Committees Other public boards Pay Source
Robert Etherington
CEO
 59 2013
13 years
 Not stated None stated None stated Paid as CEO
Shalom Jacobovitz
65 2013
13 years
 Independent
Compensation Committee · Chair
None stated Not stated
Alison H. Mosca
53 2019
7 years
 Independent
Audit Committee · Chair
None stated Not stated
Jonathon T. Gay
49 2020
6 years
 Independent None stated None stated Not stated
Vallerie V. McLaughlin, M.D.
62 2021
5 years
 Independent None stated None stated Not stated
Reed N. Wilcox
78 2013
13 years
 Independent None stated None stated Not stated
David J. Matlin
Board chair
 64 2020
6 years
 Independent
Nominating and Corporate Governance Committee · Chair
TriSalus Life Sciences Inc. Not stated
Arjun JJ Desai, M.D.
44 2023
3 years
 Independent
Compensation Committee
TriSalus Life Sciences Not stated
Matthew Kiernan AM, Ph.D., DSc
59 2023
3 years
 Independent None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

7 disclosed in the proxy filed Apr 10, 2026
4Life Research LLC
an entity controlled by David Lisonbee, a stockholder, debt holder, and board member of a subsidiary of Clene
Amount not stated
2024

Exclusive supply agreement and license agreement for dietary supplement products, amended April 25, 2024; we receive royalties and product revenue from 4Life.

Open in proxy
Kensington Clene 2024, LLC
an entity controlled by Alison Mosca, an independent director
$8.0 million
December 2024

Purchase of senior secured convertible promissory notes (2024 SSCP Notes).

Open in proxy
4Life Research LLC
an entity controlled by David Lisonbee, a 5% or greater stockholder and board member of a subsidiary of Clene
$1.0 million each
December 2024

Purchase of 2024 SSCP Notes.

Open in proxy
La Scala Investments, LLC
an entity controlled by David Lisonbee, a 5% or greater stockholder and board member of a subsidiary of Clene
$1.0 million each
December 2024

Purchase of 2024 SSCP Notes.

Open in proxy
David Matlin
an independent director and chairman of our Board
Approximately $0.5 million
October 2024

Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.

Open in proxy
Kensington Clene 2021, LLC
an entity controlled by Alison Mosca, an independent director
Approximately $0.8 million
October 2024

Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.

Open in proxy
SymBiosis II, LLC
a 5% or greater stockholder
Approximately $2.0 million
October 2024

Participation in October 2024 private placement of common stock, pre-funded warrants and common warrants.

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans